Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: The RETAIN study

British Journal of Ophthalmology

Volumn 100, Issue 6, 2016, Pages 787-795

  Prünte, Christian ^a,b,c   Fajnkuchen, Franck ^d   Mahmood, Sajjad ^e   Ricci, Federico ^f   Hatz, Katja ^a,c   Studnička, Jan ^g   Bezlyak, Vladimir ^h   Parikh, Soumil ^h   Stubbings, William John ^h   Wenzel, Andreas ^h   Figueira, João ^i,j,k  

^a Vista Klinik   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d Centre d'Imagerie et de Laser   (France)

^e MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

^f TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^g UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^j CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^k UNIVERSITY OF COIMBRA   (Portugal)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; HEART INFARCTION; HEMATOMA; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATIENT SAFETY; PERIORBITAL HEMATOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DIAGNOSTIC IMAGING; DOSE RESPONSE; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; MULTICENTER STUDY; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; TIME FACTOR;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84971411336     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-307249     Document Type: Article

References (24)

1. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1-9.
2. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012;366:1227-39.
3. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010;26:1587-97.
4. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25.
5. Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: Interim analysis of the RESTORE Extension Study. Ophthalmology 2013;120:2004-12.
6. Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE Extension study. Ophthalmology 2014;121:1045-53.
7. Elman MJ, Bressler NM, Qin H, et al, Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-14.
8. Elman MJ, Qin H, Aiello LP, et al, Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119:2312-18.
9. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015;122:375-81.
10. Spaide RF. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143:679-80.
11. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-40.
12. Abedi F, Wickremasinghe S, Islam AF, et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina 2014;34:1531-8.
13. Rayess N, Houston SK III, Gupta OP, et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. Am J Ophthalmol 2015;159:3-8.
14. Berg K, Pedersen TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015;122:146-52.
15. Oubraham H, Cohen SY, Samimi S, et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2011;31:26-30.
16. Pearce I, Banerjee S, Burton BJ, et al. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. Ophthalmology 2015;122:1811-19.
17. European Medicines Agency. Lucentis: EPAR-Product Information. EMEA/H/C/000715-IB/0032. Updated 20 July, 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000715/WC500043546.pdf (accessed 15 May 2015).
18. Bhagat N, Grigorian RA, Tutela A, et al. Diabetic Macular Edema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
19. Bretz F, Maurer W, Brannath W, et al. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009;28:586-604.
20. Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina 2013;33:1351-8.
21. Do DV, Nguyen QD, Khwaja AA, et al, for the READ-2 Study Group. Ranibizumab for oedema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013;131:139-45.
22. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-74.
23. Mercer BN, Morais S, Cubbon RM, et al. Diabetes mellitus and the heart. Int J Clin Pract 2012;66:640-7.
24. European Medicines Agency. Summary of Product Characteristics. Lucentis 10 mg/ml solution for injection. Novartis. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000715/WC500043546.pdf http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000715/WC500043546.pdf (accessed 15 May 2015)